Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548650 | 1.00 | GSR (0.53) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Water SCHEMBL380639 | 0.98 | GSR (0.52) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL28717409 | 0.96 | ARG2 (0.50) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL15516718 | 0.93 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| Lysine SCHEMBL15516717 | 0.93 | GSR (0.67) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL29485083 | 0.88 | GSR (0.61) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL359142 | 0.87 | GSR (0.55) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL2263983 | 0.87 | GSR (0.55) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL2263990 | 0.87 | GSR (0.55) | GSRCYP1A2GRM8GRM6GRIN2D | |
| SCHEMBL30433129 | 0.87 | MAOA (0.53) | GSRCYP1A2ARG2ARG1DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 670 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20250170224-A1 | METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2025-05-29 | — | — | US | claimed |
| US-12292445-B2 | Methods of selecting subjects for treatment with metabolomic modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-06 | — | — | US | claimed |
| WO-2024254556-A9 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| CN-119317362-A | Pet food compositions and methods for reducing metabolites associated with protein spoilage in felines | 希尔氏宠物营养品公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2024254556-A1 | BACTERIAL COMPOSITIONS FOR METABOLIZING UREMIC TOXINS | ATOSSA THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| EP-4429657-A1 | METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION | Ultimate Medicine AG (CH) | 2024-09-18 | — | — | EP | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-12044684-B2 | Methods for diagnosing an autistic spectrum disorder | QATAR UNIVERSITY (QA) | 2024-07-23 | — | — | US | claimed |
| EP-2690107-A2 | CYCLIC PEPTIDES WITH AN ANTI-NEOPLASIC AND ANTI-ANGIOGENIC ACTIVITY | Centro De Ingenieria Genetica Y Biotecnologia (CU) | 2014-01-29 | — | — | EP | claimed |
| CN-103534265-A | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity | CT INGENIERIA GENETICA BIOTECH | 2014-01-22 | — | — | CN | claimed |
| US-20130345175-A1 | Methods for Improving Diabetes Management | PREVENTAGE HEALTHCARE, LLC | 2013-12-26 | — | — | US | claimed |
| US-20130267455-A1 | CROSSLINKED PEPTIDE HYDROGELS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-10 | — | — | US | claimed |
| EP-2552938-A1 | AMPHIPHILIC LINEAR PEPTIDE/PEPTOID AND HYDROGEL COMPRISING THE SAME | Agency for Science, Technology And Research (SG) | 2013-02-06 | — | — | EP | claimed |
| US-20130023460-A1 | AMPHIPHILIC LINEAR PEPTIDE/PEPTOID AND HYDROGEL COMPRISING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-01-24 | — | — | US | claimed |
| WO-2011123061-A1 | AMPHIPHILIC LINEAR PEPTIDE/PEPTOID AND HYDROGEL COMPRISING THE SAME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-10-06 | — | — | WO | claimed |
| WO-2010132459-A2 | BIOMARKERS FOR ASSESSMENT OF AGE-RELATED MACULAR DEGENERATION | CLEVELAND CLINIC FOUNDATION (US) | 2010-11-18 | — | — | WO | claimed |
| US-20050124071-A1 | Methods and compositions for diagnosing musculoskeletal, arthritic and joint disorders by biomarker dating | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | claimed |
| WO-2005033705-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSING MUSCULOSKELETAL, ARTHRITIC AND JOINT DISORDERS BY BIOMARKER DATING | DUKE UNIVERSITY (US) | 2005-04-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | GSR 2589/4885CYP1A2 4682/4885GRM8 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.